Open Access

Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B‑cell lymphoma

  • Authors:
    • Huirong Ding
    • Xiaojing Cheng
    • Ning Ding
    • Zhihua Tian
    • Jun Zhu
    • Chunlian Zhou
    • Jing Shen
    • Yuqin Song
  • View Affiliations

  • Published online on: November 1, 2017     https://doi.org/10.3892/ol.2017.7318
  • Pages: 264-270
  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lysosomal protein transmembrane 4β (LAPTM4B) is an oncogene that is overexpressed in a number of various types of human cancer. There are two known alleles of LAPTM4B: LAPTM4B*1 and LAPTM4B*2. The present study assessed the association between LAPTM4B polymorphisms and the susceptibility to diffuse large B‑cell lymphoma (DLBCL) and its prognosis. LAPTM4B genotypes were determined using polymerase chain reaction analysis in 164 DLBCL and 350 healthy control cases. The association between LAPTM4B polymorphisms and the risk of DLBCL was analyzed using unconditional logistic regression. Differences in patient survival were calculated using Kaplan‑Meier analysis. The present study indicated no significant differences (P>0.05) in the frequency of LAPTM4B*2 alleles between DLBCL cases (26.5%) and controls (24.1%). The risk of DLBCL was slightly increased in cases with the LAPTM4B*1/2 genotype [odds ratio (OR)=1.160; 95% confidence interval (CI)=0.781‑1.724] or the LAPTM4B*2/2 genotype (OR=1.446; 95% CI=0.648‑3.227) compared with those with the LAPTM4B*1/1 genotype. There was no significant association between the presence of the LAPTM4B*2 allele and overall survival (OS) and disease‑free survival (DFS) in patients with DLBCL (P=0.399 and 0.520, respectively). However, there was a tendency for patients with LAPTM4B*2 and International Prognostic Index (IPI) score 3‑5 to have longer OS and DFS (P=0.126 and 0.109, respectively). These findings suggest that genetic polymorphisms of LAPTM4B is not a risk factor for the development of DLBCL, but the LAPTM4B*2 allele may a better prognostic indicator in patients with IPI score 3‑5 in DLBCL.

References

1 

International Agency for Research on Cancer, . World Cancer Report 2014. simplehttp://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014July. 2014

2 

Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 23:5027–5033. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Perry AR and Goldstone AH: High-dose therapy for diffuse large-cell lymphoma in first remission. Ann Oncol. 9 Suppl 1:S9–S14. 1998. View Article : Google Scholar : PubMed/NCBI

4 

Fisher RL, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr and Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 328:1002–1006. 1993. View Article : Google Scholar : PubMed/NCBI

5 

International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI

6 

Ruzinova MB, Caron T and Rodig SJ: Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol. 34:882–891. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, et al: An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 123:837–842. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X and Ye DX: Molecular cloning and characterization of LAPTM4B, a novel gene unregulated in hepatocellular carcinoma. Oncogene. 22:5060–5069. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Deng LJ, Zhang QY, Liu B and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. Beijing Da Xue Xue Bao. 37:302–505. 2005.(In Chinese). PubMed/NCBI

10 

Fan M, Liu Y, Zhou R and Zhang Q: Association of LAPTM4B gene polymorphism with breast cancer susceptibility. Cancer Epidemiol. 36:364–368. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Liu Y, Zhang QY, Qian N and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol. 18:311–316. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Cheng XJ, Xu W, Zhang QY and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol. 19:527–532. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Xu Y, Liu Y, Zhou R, Meng F, Gao Y, Yang S, Li X, Yang M and Lou G: LAPTM4B polymorphisms is associated with ovarian cancer susceptibility and its prognosis. Jpn J Clin Oncol. 42:413–419. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Li C, Zhou Q, Wang Y, Chen X, Yang X and Zhu D: Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. Zhongguo Fei Ai Za Zhi. 9:109–112. 2006.(In Chinese). PubMed/NCBI

15 

Wang S, Zhang QY and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of primary liver cancer. Ann Oncol. 23:1864–1869. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Wang B, Xu J, Zhou R and Zhang Q: Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population. Med Oncol. 30:4702013. View Article : Google Scholar : PubMed/NCBI

17 

Yang H, Zhai G, Ji X, Xiong F, Su J and McNutt MA: LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One. 7:e349842012. View Article : Google Scholar : PubMed/NCBI

18 

Tang H, Tian H, Yue W, Li L, Li S, Gao C, Si L, Qi L, Lu M and Hu W: LAPTM4B polymorphism is associated with non-small cell lung cancer susceptibility and prognosis. Oncol Rep. 31:2454–2460. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Meng F, Li H, Zhou R, Luo C, Hu Y and Lou G: LAPTM4B gene polymorphism and endometrial carcinoma risk and prognosis. Biomarkers. 18:136–43. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Narayanan S and Savage KJ: Staging and prognostic factorsNon-Hodgkin Lymphomas. Armitage JO, Mauch PM, Harris NL, Coiffier B and Dalla-Favera R: 2nd. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 149–171. 2010

21 

Li X, Kong X, Chen X, Zhang N, Jiang L, Ma T and Yang Q: LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis. PLoS One. 7:e449162012. View Article : Google Scholar : PubMed/NCBI

22 

Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, Rui JA and Ye DX: Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol. 10:1555–1559. 2004. View Article : Google Scholar : PubMed/NCBI

23 

Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ and Zhou RL: LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene. 29:5785–5795. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Liu X, Zhou R, Zhang Q, Zhang Y, Shao G, Jin Y, Zhang S, Lin M, Rui J and Ye D: Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene. Beijing Da Xue Xue Bao. 35:340–347. 2003.(In Chinese). PubMed/NCBI

25 

He J, Shao G and Zhou R: Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells. Beijing Da Xue Xue Bao. 35:348–352. 2003.(In Chinese). PubMed/NCBI

26 

Yang H, Xiong F, Wei X, Yang Y, McNutt MA and Zhou R: Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 294:236–244. 2010. View Article : Google Scholar : PubMed/NCBI

27 

Zhou L, He XD, Yu JC, Zhou RL, Shan Y and Rui JA: Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery. 150:25–31. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X and Ye DX: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 22:5060–5069. 2003. View Article : Google Scholar : PubMed/NCBI

29 

Milkereit R, Persaud A, Vanoaica L, Guetg A, Verrey F and Rotin D: LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation. Nat Commun. 6:72502015. View Article : Google Scholar : PubMed/NCBI

30 

Huygens C, Lienart S, Dedobbeleer O, Stockis J, Gauthy E, Coulie PG and Lucas S: Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells. J Biol Chem. 290:20105–20116. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Xiao M, Jia S, Wang H, Wang J, Huang Y and Li Z: Overexpression of LAPTM4B: An independent prognostic marker in breast cancer. J Cancer Res Clin Oncol. 139:661–667. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Zhai G, Yan K, Ji X, Xu W, Yang J, Xiong F, Su J, McNutt MA and Yang H: LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma. PLoS One. 7:e452902012. View Article : Google Scholar : PubMed/NCBI

33 

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al: The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ding, H., Cheng, X., Ding, N., Tian, Z., Zhu, J., Zhou, C. ... Song, Y. (2018). Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B‑cell lymphoma. Oncology Letters, 15, 264-270. https://doi.org/10.3892/ol.2017.7318
MLA
Ding, H., Cheng, X., Ding, N., Tian, Z., Zhu, J., Zhou, C., Shen, J., Song, Y."Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B‑cell lymphoma". Oncology Letters 15.1 (2018): 264-270.
Chicago
Ding, H., Cheng, X., Ding, N., Tian, Z., Zhu, J., Zhou, C., Shen, J., Song, Y."Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B‑cell lymphoma". Oncology Letters 15, no. 1 (2018): 264-270. https://doi.org/10.3892/ol.2017.7318